Geometry.Net - Basic_G: Graft Vs Host Disease


Home - Basic_G - Graft Vs Host Disease

e99.com Bookstore

Images

Newsgroups

21-40 of 92 Back | 1 | 2 | 3 | 4 | 5 | Next 20

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Graft Vs Host Disease: more books (19)

Cutaneous manifestations of systemic disease: sarcoidosis, GVHD, behcet's disease, and pyoderma gangrenosum.(Dermatology Nursing Essentials: Core Knowledge)(Author ... An article from: Dermatology Nursing by Sue Ann McCann, 2007-02-01

Tacrolimus: An entry from Thomson Gale's <i>Gale Encyclopedia of Cancer, 2nd ed.</i> by Diane Calabrese, 2006

Bacterial endotoxin and graft-versus-host-disease by Richard Hugh Moore, 1988

Specifically induced resistance to graft-versus-host disease in F1 rats;: A dissertation in immunology by Donald Bellgrau, 1978

Diseases caused by reactions of T lymphocytes to incompatible structures of major histocompatibility complex: Academic proefschrift / c Antonius Gerhardus Rolink by Anton G Rolink, 1983

lists with details

Graft-vs.-host Disease
a CHORUS notecard document about graftvs.-host disease graft-vs.-host disease. "GvH" seen in recipients of bone marrow allografts
http://chorus.rad.mcw.edu/doc/00177.html
Graft-vs.-host Disease
If immunogenic cells from the donor are transplanted along with the organor tissue, they will attack the host, causing graft vs. host disease.
http://www.healthatoz.com/healthatoz/Atoz/ency/graft-vs-host_disease.html

Extractions: Definition Graft-vs.-host disease is an immune attack on the recipient by cells from a donor. Description The main problem with transplanting organs and tissues is that the recipient host does not recognize the new tissue as its own. Instead, it attacks it as foreign in the same way it attacks germs, to destroy it. If immunogenic cells from the donor are transplanted along with the organ or tissue, they will attack the host, causing graft vs. host disease. The only transplanted tissues that house enough immune cells to cause graft vs. host disease are the blood and the bone marrow. Blood transfusions are used every day in hospitals for many reasons. Bone marrow transplants are used to replace blood forming cells and immune cells. This is necessary for patients whose cancer treatment has destroyed their own bone marrow. Because bone marrow cells are among the most sensitive to radiation and chemotherapy , it often must be destroyed along with the cancer. This is true primarily of leukemias, but some other cancers have also been treated this way. Causes and symptoms Even if the donor and recipient are well matched, graft-vs.-host disease can still occur. There are many different elements involved in generating immune reactions, and each person is different, unless they are identical twins. Testing can often find donors who match all the major elements, but there are many minor ones that will always be different. How good a match is found also depends upon the urgency of the need and some good luck.
Abrogation Of Graft Vs. Host Disease After Allogeneic Bone Marrow Transplantatio
DEPARTMENT OF Internal Medicine Timothy J. Ley, MD; Parul Doshi, Ph.D. Keywordsallogenetic bone marrow transplantation, graft vs. host disease, T cells
http://research.medicine.wustl.edu/ocfr/research.nsf/c517b7f27339413086256797005
University Of The West Indies Faculty Of Medical Sciences Digital Library
graft vs. host disease (GVHD). graft vs. host disease (GVHD) is a complication that may occur during the post
http://westindiesmed-dl.slis.ua.edu/clinical/dermatology/immunedisorders/graftho

Extractions: Clinical Resources by Topic: Hematology Graft vs. Host Disease Clinical Resources Pediatrics Atlases Radiology Pathology ... Miscellaneous Resources See also: Family Practice Handbook 4th Ed.-2001: Table of contents Medicine, Ob/Gyn, Psychiatry, and Surgery (eMedicine): Table of contents Dermatology (eMedicine): Table of contents CliniWeb: Homepage (includes links to targeted PubMed MEDLINE searches) Pediatrics Resources See also General Pediatrics Resources Atlases Radiology Resources See also General Radiology Resources CHORUS-Collaborative Hypertext of Radiology: Homepage Gastrointestinal System: Table of contents Small Bowel: List of documents Graft vs. Host Disease:
Dermatology Clinical Trials Unit
DEPARTMENT OF Internal Medicine Keywords Translational research, clinical trials,cutaneous tcell lymphoma, psoriasis, graft vs. host disease The Dermatology
http://research.medicine.wustl.edu/ocfr/Research.nsf/Abstracts/E36F0637A93BA4508
Three Rivers AHEC Digital Medical Libraries
Patient/Family Resources by Topic Hematology graft vs. host disease Patient/Family Resources See also General Hematology Patient/Family Resources graft vs. host disease Clinical Resources HealthSouth disease Encyclopedia Table of contents
http://threeriversahec-dl.slis.ua.edu/patientinfo/dermatology/immunedisorders/gr
Graft Vs. Host Disease: Pediatric Bone Marrow Tranplant Program
BMT Home The BMT The Transplant Process Back (After the Transplant) GVHD Next(Discharge) graft vs. host disease (GVHD). graft vs.
http://www.som.ucsf.edu/departments/pediatrics/bmt/bmt/process/gvhd.htm

Extractions: The Donor ... Next (Discharge) Graft vs. host disease ( GVHD T lymphocytes ) are infused (via a blood or platelet transfusion or a bone marrow transplant) into the recipient (i.e., the host) who has received conditioning therapy. Blood and platelets are irradiated to prevent GVHD, but the donor graft cannot be treated this way since irradiation would also kill the normal bone marrow stem cells. GVHD can take two forms, acute and chronic There are several medications that are used to help reduce the occurrence and severity of GVHD as well as to treat it when it does occur. Two drugs that are used frequently to help minimize the reaction are methotrexate and cyclosporin A . These drugs may be given singly or in combination depending upon the type of transplant and the disease. Like all drugs, these medications may have side effects including kidney and liver injury. Drugs which may be used to treat a reaction once it occurs include steroids (prednisone or methylprednisilone), cyclosporin A (if not already being administered), and anti-thymocyte globulin (ATG). In addition, there are several experimental drugs which may be offered if these standard therapies are ineffective. In a mismatched bone marrow stem cell transplant
University Of The West Indies Faculty Of Medical Sciences Digital Library
Patient/Family Resources by Topic Hematology graft vs. host disease Patient/Family Resources Miscellaneous See also General Hematology Patient/Family Resources graft vs. host disease Clinical Resources HealthSouth disease Encyclopedia Table of
http://westindiesmed-dl.slis.ua.edu/patientinfo/dermatology/immunedisorders/graf
Conditioning Regimen: Pediatric Bone Marrow Transplant Program
What it does Decreases the body's ability to reject new bone marrow. May alsobe used to treat graft vs. host disease. Made in horses or rabbits.
http://www.som.ucsf.edu/departments/pediatrics/bmt/bmt/process/conditioning.htm

Extractions: The Donor ... Next (Day of Transplant) During the "countdown period", usually lasting 5-10 days before the transplant, a conditioning regimen is administered. The drugs (chemotherapy) and/or radiation that are used vary with the underlying disease. Some children with severe immunodeficiencies may not require any chemotherapy or radiation. The overall goals of the conditioning regimen are as follows: The following are the various chemotherapy agents that the patient may receive in preparation for a bone marrow transplant. Not all of the potential side effects may occur and the toxicities vary greatly from recipient to recipient. It is important to know that most of the drugs used in conditioning regimens contribute to nausea, vomiting, hairloss, organ damage (in particular liver and kidney) and a risk of secondary malignancies. We will let you know of the most frequent side effects and those that are rare. 1. ATG (Anti-Thymocyte Globulin)
Silver Hill Hospital Digital Library
Patient/Family Resources by Topic Hematology graft vs. host disease Patient/Family Resources Spanish Miscellaneous See also General Hematology Patient/Family Resources graft vs. host disease Clinical Resources MEDLINEplus Medical Encyclopedia
http://silverhillhospital-dl.slis.ua.edu/patientinfo/dermatology/immunedisorders
Transplant Study Of Graft Vs. Host Disease -- Roswell Park Cancer Institute
Transplant Study of graft vs. host disease. Home Patients and Advocates Clinical Trials Open Clinical Trials Transplant Study of graft vs.
http://www.roswellpark.org/clinicaltrial.asp?lid=1232&reflid=389
Florida State University College Of Medicine Digital Library
graft vs. host disease Patient/Family Resources. Miscellaneous. See also GeneralHematology Patient/Family Resources; graft vs. host disease Clinical Resources.
http://fsumed-dl.slis.ua.edu/patientinfo/dermatology/immunedisorders/grafthostdi
Graft Vs. Host Disease Study: News: UI Health Care
Health Care researcher is serving as a coprincipal investigator for a NationalInstitutes of Health (NIH) grant to study graft versus host disease (GVHD) in
http://www.uihealthcare.com/news/news/2001/01/22graft.html

Extractions: University of Iowa UI Health Care News: Week of January, 20001 A University of Iowa Health Care researcher is serving as a co-principal investigator for a National Institutes of Health (NIH) grant to study Graft versus Host Disease (GVHD) in children. GVHD is a common and life-threatening complication that can follow bone marrow transplantation. Frederick Goldman, M.D., UI associate professor of pediatrics and director of the UI Pediatric Bone Marrow Transplant Unit, received $460,000 of the $2.3 million, five-year NIH grant for his component of the study. The study's lead investigator is Andrew Gilman, M.D., of Children's Mercy Hospital in Kansas City, Mo. The overall study goals are to evaluate the effectiveness of hydroxychloroquine, a new immunosuppressive drug, for treating GVHD and to better under what causes the disease, Goldman said. More than 100 pediatric bone marrow transplant centers nationwide will participate in the trial, which is sponsored by the federal Children's Oncology Group. The study will ultimately involve more than 300 pediatric patients.
Member Sign In
Is there any evidence that patients with severe acute or chronic graftvs-host-disease(GVHD) unresponsive to cyclosporine (CyA) after allogeneic stem cell
http://www.medscape.com/viewarticle/414096
Member Sign In
Bone Marrow and Stem Cell Transplantation Ask The Expert Treatment of PulmonaryGraftvs-host disease (GVHD) With IL-2 Receptor Inhibitors?
http://www.medscape.com/viewarticle/414085
September 1992 - Transfusion Associated Graft Vs. Host Disease And Irradiated Bl
irradiation. Additional information about Transfusion Associated Graftvs host disease can be obtained by contacting Darrell J. Triulzi, MD.
http://www.itxm.org/Archive/tmu9-92.htm

Extractions: TRANSFUSION ASSOCIATED GRAFT VS. HOST DISEASE AND IRRADIATED BLOOD COMPONENTS Darrell J. Triulzi, M.D., Assistant Medical Director, Patient Transfusion Services INTRODUCTION Graft vs. host disease is a rare complication of transfusion. The disease results from transfusion of immunocompetent T cells capable of engrafting and initiating an immune response against recipient antigens. The most susceptible patient groups are those who are severely immunocompromised or are the recipients of directed donations from first-degree relatives. Transfusion associated graft vs. host disease (TAGVHD) can be prevented by gamma irradiation of cellular blood components (red cells, platelets, granulocytes). CLINICAL PRESENTATION TAGVHD has the same features as graft vs. host disease occurring in other settings such as allogeneic bone marrow transplantation. It typically occurs 3-30 days after transfusion of non-irradiated cellular products. The initial manifestations are often a high fever and an erythematous skin rash. Bone marrow aplasia and pancytopenia are also characteristic findings in TAGVHD. Other organs which may be involved include the gastrointestinal tract and liver. The diagnosis is made on the basis of a constellation of clinical features and can be confirmed by biopsy of the skin or other involved organs. This form of GVH has an extremely poor prognosis; the mortality rate approaches 90%. Unfortunately, there are no current effective therapies.
Photopheresis For Chronic Graft Vs. Host Disease
Photopheresis for Chronic graft vs. host disease. This educational resourceis supported by an unrestricted educational grant from therakos.logo.gif
http://www.bloodline.net/stories/storyReader$3374
Extracorporeal Phtopheresis In Acute Graft Vs. Host Disease
Extracorporeal Phtopheresis in Acute graft vs. host disease. This educational resourceis supported by an unrestricted educational grant from therakos.logo.gif
http://www.bloodline.net/stories/storyReader$3375
Graft Vs Host Dis 1999
Abgenix Initiates Phase III Clinical Trial of graft Versus host disease TherapyAbgenix to Seek a Corporate Partner to Commercialize ABXCBL - FREMONT, Calif
http://organtx.org/dc/gvh1999.htm

Extractions: ORONTO(BW HealthWire)Dec. 14, 1999Vasogen Inc. (TSE:VAS.) (AMEX:MEW) today announced results of the final phase of the Company's pre-clinical research in the prevention of Graft-versus-Host Disease (GvHD). These results have supported regulatory submissions to commence a clinical trial of its VAS981 cell processing technology in the prevention of GvHD. GvHD is a potentially fatal complication of bone marrow transplantation performed to treat leukemias and other types of cancer that no longer respond to conventional therapy. GvHD develops as part of an immune response that occurs when T cells, given with the donated bone marrow (graft), identify cells in the recipient's body (host) as foreign and reject them. GvHD causes symptoms ranging from anorexia and severe vomiting to malabsorption and liver dysfunction. The costs of treating the complications of GvHD exceed $400 million annually. Previously announced results from research conducted at the Division of Cancer Biology Research, Sunnybrook Health Science Centre, University of Toronto, under the direction of Dr. David Spaner, demonstrated that the treatment of donor immune cells with VAS981 prior to transplantation prevented GvHD in animal models. Recently completed research extended these studies to investigate the effects of VAS981 on human immune cells that are administered in bone marrow grafts and cause GvHD. The results showed that VAS981-treated cells produced much lower levels of the inflammatory cytokines that are associated with GvHD. The in vitro changes seen in these laboratory studies on human cells closely mirrored those seen in vivo in the pre-clinical models, where they were associated with a dramatic reduction in GvHD.
Acute And Chronic Syngeneic Graft-vs-Host Disease
Acute and Chronic Syngeneic graftvs-host disease. Complexity of EffectorMechanisms in Cyclosporine-Induced Syngeneic graft-vs-host disease.
http://bbmt.cjp.com/stories/storyReader$51

Extractions: Journal Center Complexity of Effector Mechanisms in Cyclosporine-Induced Syngeneic Graft-vs-Host Disease Allan D. Hess, Christopher J. Thoburn, Weiran Chen and Louis R. Horwitz Administration of the immunosuppressive drug, cyclosporine after syngeneic or autologous bone marrow transplantation elicits a T-lymphocyte-dependent autoimmune syndrome similar to graft-vs-host disease (GVHD). The onset of this autoaggression syndrome, termed syngeneic GVHD, is associated with the development of a highly restricted repertoire of CD8 autoreactive T cells that recognize a peptide from the invariant chain, termed CLIP, presented by MHC class II molecules. Clonal analysis reveals two distinct subsets of autoreactive T cells defined by their activation requirement for either the N terminal or the C terminal flanking regions of CLIP and by their cytokine profile. The present studies reveal that the autoreactive T cell clones requiring the N terminal flanking region of CLIP produce type 1 cytokines (interferon [IFN]- y , interleukin [IL]-2, and tumor necrosis factor- a ). In contrast, the autoreactive T cell clones that require the C terminal flanking region of CLIP produce type 2 cytokines (IL-4, IL-10, Transforming growth factor-

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

21-40 of 92 Back | 1 | 2 | 3 | 4 | 5 | Next 20